AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23092239
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo lozenges)
Trial: 27708111
Drug: Zofenopril 60
RxNorm normalized name: Zofenopril
DrugBank: Zofenopril (DB13166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril 60 mg plus acetylsalicylic acid (ASA) 100 mg
Trial: 27708111
Drug: Ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 10 mg plus ASA
Trial: 23747777
Drug: Rivaroxaban (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (a factor Xa inhibitor)
Trial: 23747777
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (dual antiplatelet therapy)
Trial: 17375118
Drug: Virgin olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virgin olive oil (50 ml daily)
Trial: 28892591
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg twice-weekly
Trial: 10737480
Drug: BCG maintenance
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG maintenance therapy (intravesical and percutaneous BCG each week for 3 weeks at 3, 6, 12, 18, 24, 30, and 36 months)
Trial: 10737480
Drug: No BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No BCG maintenance therapy
Trial: 23452187
Drug: BCG maintenance
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG maintenance therapy
Trial: 1578910
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation therapy (including allogeneic and autologous bone marrow transplantation)
Trial: 1578910
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (3 gm/M2/day IV on days 1-6)
Trial: 1578910
Drug: Conventional induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional induction therapy +/− GM-CSF
Trial: 2860167
Drug: Daily antiseptic
RxNorm normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antiseptic mouthwash with chlorhexidine‐gluconate
Trial: 2860167
Drug: Daily antiseptic
RxNorm normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antiseptic mouthwash with povidone‐iodine
Trial: 2860167
Drug: Hygienic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hygienic treatment alone
Trial: 31179831
Drug: Levothyroxine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (20 μg bolus followed by 20 μg/h infusion)
Trial: 21816692
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for diabetes
Trial: 16458200
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid supplementation (500 mg, twice daily; 2 weeks)
Trial: 9213203
Drug: bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol (10 mg q.d.)
Trial: 9213203
Drug: lisinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril (20 mg q.d.)
Trial: 10779310
Drug: 0.05 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/m2 rIFN-gamma
Trial: 3315914
Drug: oral ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral ketanserin (20 mg X 7)
Trial: 27132409
Drug: DermoXEN Vitexyl
RxNorm normalized name: Dermoneen
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DermoXEN Vitexyl vaginal gel
Trial: 24604487
Drug: Shared care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shared care model of follow-up visits in the first 12 months after treatment, including a survivorship care plan, GP management guidelines, register and recall systems, screening for distress and unmet needs, and patient information resources.
Trial: 23690424
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus brivanib 800 mg orally daily
Trial: 16630383
Drug: Twice-weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly iron supplementation (ferrous dextran, 60 mg elemental iron)
Trial: 8911006
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms OprI vaccine
Trial: 8911006
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms OprI vaccine
Trial: 8911006
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms OprI vaccine
Trial: 8911006
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms OprI vaccine
Trial: 1729038
Drug: Continuous iv
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous iv infusion of furosemide (initial dose 0.1 mg/kg iv, infusion rate 0.1 mg/kg.hr, doubled every 2 hrs to max 0.4 mg/kg.hr)
Trial: 1729038
Drug: Intermittent iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent iv infusion of furosemide (1 mg/kg iv every 4 hrs, increased by 0.25 mg/kg every 4 hrs to max 1.5 mg/kg)
Trial: 6339571
Drug: Thymopoietin pentapeptide
RxNorm normalized name: pentapeptide-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopoietin pentapeptide (TP-5) 50 mg, thrice-weekly injections for 6 weeks
Trial: 31607271
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (part of a randomized trial)
Trial: 25160064
Drug: Weekly standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly standardized SMS
Trial: 25160064
Drug: Weekly standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly standardized supervisory visits
Trial: 18728038
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of low-dose aspirin (Control)
Trial: 11087965
Drug: mCPP (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mCPP (0.5 mg/kg body weight)
Trial: 3282893
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg b.i.d. (increased to 10 mg b.i.d. if needed)
Trial: 3282893
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg b.i.d. (increased to 25 mg b.i.d. if needed)
Trial: 11341663
Drug: Coffee (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee (280 ml)
Trial: 29374995
Drug: Intraosseous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection (IO)
Trial: 20665501
Drug: IA combination
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA combination (idarubicin and cytarabine)
Trial: 17602073
Drug: Bevacizumab 5
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5 mg/kg infused over 10 minutes
Trial: 17602073
Drug: Bevacizumab 5
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5 mg/kg infused over 30 minutes
Trial: 17602073
Drug: Bevacizumab 5
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5 mg/kg infused at a standard rate of 0.5 mg/kg/min
Trial: 16040284
Drug: Levofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (300 mg b.d.)-based therapy with lansoprazole (30 mg b.d.) and amoxicillin (1000 mg b.d.) for 7 days
Trial: 16040284
Drug: Metronidazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (500 mg b.d.)-based therapy with lansoprazole (30 mg b.d.) and amoxicillin (1000 mg b.d.) for 7 days
Trial: 12556743
Drug: Catheter-directed thrombolytic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter-directed thrombolytic therapy using urokinase
Trial: 12556743
Drug: Catheter-directed thrombolytic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter-directed thrombolytic therapy
Trial: 12556743
Drug: Anticoagulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation with unfractionated or low molecular weight heparin followed by warfarin
Trial: 7795270
Drug: TMQ at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMQ at 200 mg/m2 i.v. q 2 weeks
Trial: 7795270
Drug: TMQ at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMQ at 12 mg/m2 i.v. daily x 5
Trial: 7795270
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) at 15 mg/kg i.v. weekly
Trial: 6971922
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplement of 400 IU/day
Trial: 29390477
Drug: Drotaverine hydrochloride
RxNorm normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotaverine hydrochloride (DHC) 80‐mg tablet, 3 times daily for 4 weeks
Trial: 29390477
Drug: Placebo 80‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 80‐mg tablet, 3 times daily for 4 weeks
Trial: 22000773
Drug: Intracoronary adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary adenosine (120 μg for the right coronary artery and 180 μg for the left coronary artery)
Trial: 19685728
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) of Ashi-point, Jiaji (EX‐B 2), Zhigou (SJ 6) and Houxi (SI 3), once daily for 10 times
Trial: 19685728
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (valaciclovir hydrochloride 300 mg/time, b.i.d. and vitamin B1 10 mg/time, t.i.d., for 10 days)
Trial: 15640898
Drug: Solanum melongena
RxNorm normalized name: SOLANUM MELONGENA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solanum melongena (SM) 450 mg twice daily
Trial: 15640898
Drug: Placebo 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 450 mg twice daily
Trial: 11584350
Drug: Telephone nursing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone nursing intervention weekly for 3 months
Trial: 10099041
Drug: Tiagabine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (titrated from 8 to 24 mg/d)
Trial: 8136389
Drug: Hypodense solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypodense solution of mannitol (n = 23)
Trial: 8136389
Drug: Suspension of
RxNorm normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of BaSO4 (n = 14)
Trial: 2491962
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (hexamethylmelamine, 5‐fluorouracil, cisplatin, and prednimustine)
Trial: 23451885
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GBE) 120 mg twice daily
Trial: 18854724
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER < or =225 mg/day
Trial: 16614416
Drug: CAF in
RxNorm normalized name: Zincaf Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF in capsule form (4.45 mg/kg body weight)
Trial: 16614416
Drug: RCOF (4.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCOF (4.45 mg/kg body weight caffeine)
Trial: 31488494
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral azithromycin (20 mg/kg)
Trial: 7688381
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (200 mg orally) 12 hours before surgical interruption
Trial: 7688381
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (200 mg orally) 24 hours before surgical interruption
Trial: 3091164
Drug: Captopril (25‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25‐50 mg twice a day)
Trial: 3091164
Drug: Captopril (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12 weeks treatment)
Trial: 24646101
Drug: GnRH analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH analog injections plus daily topical testosterone gel
Trial: 18636265
Drug: Single intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of 1.25 mg bevacizumab
Trial: 18636265
Drug: Second injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second injection of bevacizumab after a mean of 19+/‐8 weeks
Trial: 18636265
Drug: Second injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second injection of bevacizumab
Trial: 17336650
Drug: Mild treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild treatment (mild ovarian stimulation with GnRH antagonist co-treatment and single embryo transfer)
Trial: 17336650
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (stimulation with GnRH agonist long-protocol and transfer of two embryos)
Trial: 17336650
Drug: Mild treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild treatment
Trial: 12691137
Drug: Tyrosine-kinase inhibitor
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tyrosine-kinase inhibitor STI 571
Trial: 29164312
Drug: Rotigotine in
RxNorm normalized name: Product containing rotigotine in transdermal dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine in combination with levodopa
Trial: 20368905
Drug: Iloperidone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloperidone (12 to 24 mg)
Trial: 16633107
Drug: Octreotide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (300 microg twice per day) with diuretics (furosemide and spironolactone)
Trial: 16633107
Drug: Octreotide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (300 microg twice per day) alone
Trial: 16633107
Drug: Diuretics (furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (furosemide and spironolactone) alone
Trial: 16633107
Drug: Diuretics (furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (furosemide and spironolactone) discontinued for 7 days
Trial: 1405984
Drug: Sucralfate, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate, given four times daily for 10 days as a swish and swallow
Trial: 4078027
Drug: Intravenous indoprofen
RxNorm normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous indoprofen 200 mg
Trial: 4078027
Drug: Intravenous indoprofen
RxNorm normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous indoprofen 400 mg
Trial: 4078027
Drug: Intramuscular pentazocine
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pentazocine 15 mg
Trial: 4078027
Drug: Intramuscular pentazocine
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pentazocine 30 mg
Trial: 28358246
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blocker (ARB)
Trial: 22951521
Drug: Non-dihydropyridine calcium
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-dihydropyridine calcium channel blocker (CCB)
Trial: 18677237
Drug: Chronic protection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic protection (1 week prophylactic use of the solution)
Trial: 18677237
Drug: Unprotected (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unprotected (no test solution used)
Trial: 18677237
Drug: Immediate protection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate protection (test solution instilled just before application of TST)
Trial: 18677237
Drug: Relief (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relief (test solution instilled just after application of TST)
Trial: 10390264
Drug: Oral cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cefixime for 14 days (double dose on day 1)
Trial: 10390264
Drug: Initial intravenous
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial intravenous cefotaxime for 3 days followed by oral cefixime for 11 days
Trial: 8814691
Drug: Oral pamidronate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pamidronate, 300 mg/day (n = 65)
Trial: 2004793
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (20 mg)
Trial: 2004793
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 ml dextrose)
Trial: 23422357
Drug: Caffeine intake
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine intake (high quintile >371 mg/day)
Trial: 21703023
Drug: Clinician reminders
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician reminders to reconsider aspirin
Trial: 21703023
Drug: Clinician and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician and patient messages to reconsider aspirin
Trial: 19335932
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) plus Treatment as Usual (TAU)
Trial: 15498043
Drug: Daily supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplement of vitamins (50 mg/day of vitamin E and 250 mg/day of vitamin C)
Trial: 11280825
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy (FLEC protocol), median of 3.5 cycles
Trial: 11280825
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy (FLEC protocol)
Trial: 8168798
Drug: Psychiatric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric treatment in jail
Trial: 2889457
Drug: CGP 361
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 361 A (10 mg)
Trial: 25957748
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dronabinol (Marinol®)
Trial: 25957748
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg dronabinol (Marinol®)
Trial: 22553980
Drug: Dronabinol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (10 mg and 20 mg)
Trial: 21327759
Drug: Nicotine administration
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine administration in abstinent smokers
Trial: 21327759
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration in abstinent smokers
Trial: 21327759
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration in abstinent smokers
Trial: 15176654
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg formulation 1
Trial: 15176654
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg formulation 2
Trial: 15176654
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg formulation 1 and 2
Trial: 11205494
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for Helicobacter pylori infection and daily dietary supplementation with antioxidant micronutrients